Vs 3X Gold (UGLD) 13.30 $UGLD As Investors Flee to

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vs 3X Gold (UGLD) 13.30 $UGLD

As Investors Flee to Safety, Buy These Leveraged Gold ETFs
Zacks Premium Research - Zacks Investment Research - Thu Jun 16, 3:08PM CDT
If a Brexit happen, things could get chippy on the global scale, so don't risk being unprotected.
UGLD: 13.30 (+0.40), DGP: 27.58 (+0.43)

Gold ETFs to Continue Their Bull Run: Here's Why?
Sweta Killa - ZACKS - Wed May 11, 5:05AM CDT
We have highlighted some strong reasons to remain invested in gold ETFs or buy on pullbacks.
SGOL: 129.02 (+1.22), UGLD: 13.30 (+0.40), GLD: 126.57 (+1.28), IAU: 12.78 (+0.13), DGP: 27.58 (+0.43), UGL: 44.73 (+0.80)

How to Trade in Gold ETFs After Robust 30-Year Rally?
Sweta Killa - Zacks Investment Research - Mon Apr 11, 10:27AM CDT
The strongest Q1 rally of the yellow metal seems fading with the stability in the financial market and an improving U.S. economy.
DGLD: 43.41 (-1.29), DGZ: 13.59 (+0.01), OUNZ: 13.13 (+0.11), UGLD: 13.30 (+0.40), GLD: 126.57 (+1.28), IAU: 12.78 (+0.13), DGP: 27.58 (+0.43), GLL: 69.42 (-1.34), UGL: 44.73 (+0.80)

Gold is Shining: Go Long With These ETFs
Sweta Killa - Zacks Investment Research - Thu Jan 21, 7:48AM CST
Given the concerns over global economic growth, the appeal for the gold ETFs as a store of wealth and a hedge against market turmoil seem brightening.
UGLD: 13.30 (+0.40), GLD: 126.57 (+1.28), DGP: 27.58 (+0.43), UGL: 44.73 (+0.80)

Direxion to Close Triple Leveraged Bull Gold ETF - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Mon Jun 01, 6:00AM CDT
Direxion is about to close its triple leveraged gold ETF having a long exposure to the gold bullion.
UGLD: 13.30 (+0.40), BAR: 27.37 (+0.27), UGL: 44.73 (+0.80)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Huawei Introduces Innovative Wearables for Enhanced Connectivity

Updated Category News Views 293

Huawei Unveils Next-Generation Wearables and Tablets At a much-anticipated event, Huawei Consumer Business Group (CBG) revealed a thrilling array of new products. This launch showcased a strong emphasis on trendy wearables and sophisticated tablets, highlighting the brand's dedication to innovation and a user-friendly design. Chic Wearables for Style and Utility Among the...

Continue Reading
Investigating Barnes & Noble Education: Shareholder Rights Explained

Updated Category News Views 155

Understanding the Investigation of Barnes & Noble Education In a proactive move for investors, the law firm Bragar Eagel & Squire, P.C. is currently investigating Barnes & Noble Education, Inc. (BNED). This investigation aims to determine whether the company potentially breached federal securities laws or engaged in unlawful business practices that could lead to...

Continue Reading
Bailey Kennedy Achieves Landmark Legal Win for Talisman Group

Updated Category News Views 171

Bailey Kennedy Achieves Legal Victory for Talisman Group Judge Rules LNW Violated Talisman's Distribution Agreement by Marketing Competing Game In a significant legal development, Bailey Kennedy, LLP has successfully represented The Talisman Group, LLC, the innovative minds behind EZ Baccarat. The firm has recently triumphed in a legal dispute against LNW Gaming, Inc.,...

Continue Reading
Join the Class Action Lawsuit Against Ardelyx, Inc. Now

Updated Category News Views 49

Join the Class Action Lawsuit Against Ardelyx, Inc. Attention Ardelyx, Inc. investors! There's an important class action lawsuit underway, and this is your opportunity to get involved. Bronstein, Gewirtz & Grossman, LLC, a respected law firm known for its dedication to investor advocacy, has announced a class action case involving Ardelyx, Inc. (NASDAQ: ARDX) and certain...

Continue Reading
Aileron Therapeutics Unveils Q3 2024 Financial Performance

Updated Category News Views 97

Aileron Therapeutics Reports Impressive Q3 2024 Financial Results Aileron Therapeutics, Inc. (NASDAQ: ALRN), a biopharmaceutical company committed to developing innovative medicines for orphan pulmonary diseases, has recently showcased significant progress with their third-quarter financial results. This quarter has been marked by promising advancements in clinical trials...

Continue Reading